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Abstract
Background: Myotonic dystrophy type 1 (DM1) is a multisystem disorder that demonstrates variable symptoms and 
rates of progression. Muscle weakness is considered one of the main problems with a clinical picture that is 
characterized by distal weakness of the limbs progressing to proximal weakness. The main objective of this study was 
to characterize the maximal strength of ankle eversion and dorsiflexion in DM1 patients. Manual and handheld 
dynamometer (HHD) muscle testing were also compared.
Methods: The maximal strength of 22 patients from Quebec (mean age = 41,1 ± 13,8) and 24 from Lyon (mean age = 
41,6 ± 10,2) were compared to 16 matched controls.
Results: With the use of HHD, an excellent reproducibility of the torque measurements was obtained for both centers 
in eversion (R2 = 0,94/Quebec; 0,89/Lyon) and dorsiflexion (R2 = 0,96/Quebec; 0,90/Lyon). The differences between 3 
groups of DM1 (mild, moderate, severe) and between them and controls were all statistically significant (p < 0,001). No 
statistical differences between sites were observed (p > 0.05). The degree of muscle strength decline in dorsiflexion 
(eversion) were 60% (47%), 77% (71%), and 87% (83%) for DM1 with mild, moderate, and severe impairments, 
respectively. The smallest mean difference between all DM1 patients taking together was 2.3 Nm, a difference about 
twice than the standard error of measurement. There was a strong relationship between eversion and dorsiflexion 
strength profiles (R2 = 0,87;Quebec/0,80;Lyon). Using a 10-point scale, manual muscle testing could not discriminate 
between the 3 groups of DM1 patients.
Conclusions: The HHD protocol showed discriminative properties suitable for multicentre therapeutic trial. The 
present results confirmed the capacity of quantitative muscle testing to discriminate between healthy and DM1 
patients with different levels of impairments. This study is a preliminary step for the implementation of a valid, reliable 
and responsive clinical outcome for the measurement of muscle impairments with this population.
Background
Myotonic dystrophy type 1 (DM1) is an autosomal domi-
nant disorder that is the most common inherited myopa-
thy in adults[1]. In Quebec (Canada), a prevalence of 189
per 100,000 population has been reported in the
Saguenay-Lac-Saint-Jean region, which is more than 13
times the highest population world-wide prevalence
reported [1,2]. DM1 is a multisystem disorder that dem-
onstrates variable symptoms and rates of progression.
Muscle weakness is considered one of the main problems
with a clinical picture that is characterized by distal weak-
ness of the limbs progressing to proximal weakness. The
progression of a general weakness of all lower limb mus-
cles, often worse in the distal muscles, will lead to reduce
balance and bilateral foot drop. Indeed, people with DM1
often present with weakness of the ankle dorsiflexor mus-
cles that may lead to falls due to tripping [3,4].
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Page 2 of 9Previous studies with myotrophic dystrophy have char-
acterized muscle strength deficits, established baseline
data and compared the rate of change in strength of prox-
imal and distal muscles. Different tools were used to
assess the muscular impairments including manual mus-
cle testing, timed functional tests, quantitative motor
evaluation, isokinetic systems, Jamar dynamometer, and
hand held dynamometers [2-7]. From those studies, few
consensuses have emerged. Distal weakness first appears
and is usually identified after 9 to 10 years' duration of the
illness. There is a faster decline for distal than for proxi-
mal muscles, and functional activities such as gait are
rapidly affected and lead to a significant level of disability.
The rate of change in muscle strength during the natural
course of disease or during rehabilitation is significant
but slow and may be difficult to detect using manual
muscle testing or ordinal scales. Manual muscle testing,
even when using reliable scales, lacks sensitivity to detect
subtle changes in muscular impairment and is not appro-
priate to measure the efficacy in short-term therapeutic
trials, and neither suitable for longitudinal studies for
which a discriminatory measure is required [8].
Hand held dynamometer (HHD) protocols represent a
good option for quantitative muscle testing in a clinical
setting. HHDs are portable, economic, and user-friendly.
The use of HHD provides a quick, simple, valid, reliable
and sensitive outcome measurement of the human mus-
cle strength and a high level of agreement can be
obtained with this type of quantified muscle testing [9-
15]. Mathieu et al. (2003) used a Nicholas push HHD to
measure the maximal isometric force of elbow extension,
hip flexion, and ankle dorsiflexion [2]. In a previous work,
we developed a standardised protocol to assess the maxi-
mum isometric torque (MIT) with the use of a HHD for
several muscle groups of both the lower and upper limbs.
The feasibility, intra- and inter-rater reliability, and con-
current validity of this protocol with the Cybex dyna-
mometer were found to be very good to excellent (Hébert
LJ et al., World Congress of Physical Therapy, Vancouver,
BC, Canada, June 2007). Also, the concurrent validity of
the HHD protocol with the Cybex was good to very good
with ICCs values of 0.79 (evertors) and 0.84 (dorsiflex-
ors).
In view of future therapeutic trials for DM-1 patients,
ankle dorsiflexor and evertor muscles could be used to
monitoring the efficacy of treatment. These muscles are
affected early in the disease progression and are easy to
inject and analyze. Also, as the evertors are the best pro-
tection for a near-maximally inverted ankle at footstrike,
they act in synergy with the ankle dorsiflexors to stabilise
the foot-ankle complex during weight bearing activities
and they may compensate for a lack of dorsiflexion [16].
In view of future therapeutic trials for DM1 patients,
ankle dorsiflexor and evertor muscles could be used to
monitoring the efficacy of gene therapy following sys-
temic or multisite intramuscular injections of either viral
vectors or antisense oligonucleotides. Therefore, in the
current study, both the ankle evertors and dorsiflexors
were considered.
The objectives of this study were to characterize the
maximal isometric strength of ankle evertors and dorsi-
flexors with HHD quantitative muscle testing in DM1
patients to establish the intra- and inter reliability, which
is of major importance for future multicentric therapeu-
tic trials. Manual and quantitative muscle testing were
also compared to provide data to validate the most appro-
priate method for monitoring muscular changes in




Inclusion criteria were limited to DM1 patients older
than 18 years old, weakness of the tibialis anterior (TA) as
assessed by manual muscle testing, DM1 diagnosis con-
firmed by molecular testing, and to the patient' ability to
take part in manual and quantified muscle strength
assessment. Patients with congenital form of the disease,
cognitive impairments, Body Mass Index (BMI) > 30,
pregnant women, and severe pulmonary deficiencies
were excluded from the study. Patients with congenital or
juvenile DM, severe pulmonary deficiencies (FVC < 50%)
and severe sleepiness were excluded: the latter two
groups were excluded because they would not have been
able to undergo the full research protocol. Patients were
recruited from the medical chart based on the manual
testing scores of the TA to ensure a wide distribution of
muscle impairment from mild (≥ 4 et < 5), to moderate (≥
3 et < 4), and severe (< 3). At the inclusion in the study, all
DM1 patients and controls recruited were tested using
the conventional 0-5 manual muscle testing scale. There-
after, using the Modified Research Council Scale (MRCS)
with a 0 to 10 point scoring system, all patients were
assessed by the physiotherapist and classified according
to the score obtained in: Group 1 (G1, mild) for a score
from 7 to10, Group 2 (G2, moderate) for a score from 4 to
6, and Group 3 (G3, severe) for a score from 0 to 3 [2].
A sample of convenience of 22 patients (M/F 11/11) in
Quebec and 24 patients in Lyon (France) (M/F 11/13)
with different levels of muscle impairments participated
in the study. A random probabilistic sample of 16 control
subjects (G0) was established using the members of the
patient family as paired subjects for age and gender. For
all controls, the molecular testing was negative, they were
not affected by any muscular pathology.
The project was approved by the ethic committees of
the IRDPQ for Quebec and of the Cardio-neurology Hos-
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Page 3 of 9pital for Lyon. Written informed consent was obtained
from all patients and controls prior to the examination.
Procedures
Manual muscle testing
A physiotherapist using manual muscle testing assessed
the maximum isometric muscle strength of the ankle dor-
siflexors and evertors. Both muscle groups were assessed
with the subject sitting on the edge of a table, both legs
hanging, the ankle at 90° of flexion. The subject was first
asked to do a full dorsiflexion or an eversion of the ankle
as far as possible. At the end of the movement, the exam-
iner was doing a break test trying to break the resistance
toward the plantar flexion (to assess the dorsiflexors) or
inversion (to assess the evertors). For both muscle
groups, a modified version of the modified MRCS (MM-
MRSC) with a 0 to 10 point scoring system was used to
quote the muscle group [5]. The lowest score obtained
was used to classify the subject. The same physiotherapist
was completing both manual and quantitative muscle
testing within the same session. The definitions of the
individual muscle testing grades and corresponding
scores of the MM-MRSC used are presented in Addi-
tional file 1.
Quantitative muscle testing
The new generation of push-pull HHDs are more accu-
rate and sensitive and they offer a better ergonomic
design for the examiner to resist different muscle groups
in several alternative positions. The maximum isometric
muscle strength of the ankle dorsiflexors and evertors
was assessed with a Chatillon push-pull hand-held dyna-
mometer (FCE-500, Ametek TCI Division, Chatillon
Force Measurement Systems, Florida, USA). All physio-
therapists received an extensive training on the use of the
standardized HHD protocol. The Figure 1 shows the
positioning of the subject that was standardised to ensure
that «gravity eliminated» positions were used for each
muscle group [14]. Both ankle dorsiflexors and evertors
were tested with the subject supine with a small roll
under the knee to allow 5-10° degrees of knee flexion,
ankle maintained at 90° of flexion. Isometric make tests
were used because they are more reliable[17,18], more
comfortable for the patient, and have shown a lower risk
for injury compared to break tests[10]. Standard verbal
encouragement was given during each maximal contrac-
tion. Two trials were completed for each muscle group,
and the mean of the two trials was used for the final anal-
ysis. When more than 10% difference was noted between
the two trials, a third one was completed. The units of
force in Newton were multiplied by the corresponding
lever arm, measured in metre, to calculate the maximal
isometric torque in Newton-meters (Nm).
Before each trial, the subject was asked to perform two
sub-maximal contractions of about 50% to warm-up,
ensure the task was well understood and verify that the
stabilisations were adequate. Subjects were instructed to
avoid explosive contraction and to increase their effort
gradually to their maximum immediately after hearing
the signal «3,2,1, GO». The tone and words of encourage-
ment used by the tester were also matching a crescendo
pattern to make sure the maximum contraction was pro-
duced at every trial. Each contraction was held 10 sec-
onds (the dynamometer was recording the peak force)
maximal force was followed by a 60 second-rest period.
Due to the lower level of endurance and fatigue of some
patients, additional and sufficient resting time was given
before proceeding to a second trial. Strength measure-
ments were tested bilaterally and values were averaged
for the two sides. At baseline, strength was measured at
day one (D1) and 21 days later (D21) by one experienced
physiotherapist (one in Quebec and one in Lyon). When
testing at D21, the tester was blind about the subject's
strength values obtained at D1.
Preliminary testing for reliability
Even though the HHD protocol used has shown excellent
psychometric properties, the specific inter-rater reliabil-
ity of the evaluators of the current study was verified.
Three examiners, the two experienced physiotherapists
appointed to the study at each centre and one backup for
the Quebec site, assessed 9 healthy subjects with the
above HHD protocol. The inter-rater reliability was then
calculated using Pearson correlation coefficients. The
above protocol was used as described except that 5 trials
per muscle group were completed.
Data analysis
Descriptive statistics (mean and standard deviations) of
maximal torques were calculated for ankle evertors and
dosrsiflexors of patients of all groups and controls. Paired
t-tests were used to verify significant statistical differ-
Figure 1 The maximum isometric muscle strength of the ankle 
evertors (A) and dorsiflexors (B and C) was assessed with a Chatil-
lon push-pull hand-held dynamometer. The positioning of the sub-
ject was standardised ensuring that «gravity eliminated» positions 
were used for each muscle group.
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sions were used to determine the relationships between
the maximal strength between evertors and ankle dorsi-
flexors for both centres (Lyon and Quebec). Maximal
torques obtained with the HHD quantitative muscle
strength assessment were plotted against the scores
obtained with the manual muscle strength assessment
from the MMRC to verify the discriminative properties of
manual muscle testing. The original alpha level for the
statistical analyses was set at 0.05.
Results
Prior to the study, preliminary testing using the above-
described HHD protocol was done. Three physiothera-
pists assessed a total of nine healthy subjects over two
sessions. Five trials per muscle group per side were com-
pleted. Results showed a good to excellent inter-rater reli-
ability between all testers with Pearson correlation
coefficients (rp) ranging from de 0.70 to 0.93 and 0.72 to
0.94 for ankle dorsiflexion and eversion, respectively.
Also, the Standard Error of Measurement (SEM) was 1.0
Nm for the dorsiflexion, and 1.3 Nm for eversion.
The 22 patients (11 males and 11 females; 11 in G1, 6 in
G2, and 5 in G3) from Quebec and the 24 from Lyon (11
males and 13 females; 11 in G1, 6 in G2, and 7 in G3) who
participated to the study had a mean age of 41,1 ± 13,8
(patients from Quebec) and 41,6 ± 10,2 (patients from
Lyon). Most of patients had myotonia but did not receive
any drugs. The matched control group was composed of
16 healthy subjects including 7 persons (5 males and 2
females) from Quebec with a mean age of 43,1 ± 9.0, and
9 persons (7 males and 2 females) from Lyon with a mean
age of 45,7 ± 9,0. In the present study, the mean number
of years of disease duration were 19.2 (G1), 30.2 (G2) and
26.6 (G3).
As observed on the Figure 2, an excellent reproducibil-
ity of the torque measurements at baseline were obtained
between Day 1 and Day 21 for both centers in eversion
(R2 = 0,94 for Quebec and 0,89 for Lyon) as well as in
ankle dorsiflexion (R2 = 0,96 for Quebec and 0,90 for
Lyon).
The torques values of ankle evertors and dorsiflexors of
all groups for both centers are reported in detail in the
Table 1. The same data is graphically reported and shown
in Figure 3a. The differences between the three DM1
groups as well as between the DM1 patients and the con-
trols were all statistically significant (p < 0,01). However,
when comparing the data between Lyon and Quebec, no
statistical differences between sites for each group were
observed (p > 0.05). Therefore, the pooled data at base-
line for both sites is reported in Figure 3b. As observed on
this Figure, the progression of muscular impairment in
ankle dorsiflexion (eversion) demonstrates a degree of
muscle strength decline of 60% (47%), 77% (71%), and
87% (83%) between the control subjects and the patients
with mild, moderate, and severe impairments, respec-
tively.
As shown on Figure 4, for both centres, there is a strong
relationship between eversion and ankle dorsiflexion
peak torques obtained with the HHD with coefficients of
determination (R2) of 0,87 and 0,80 for Quebec and Lyon,
respectively.
The Figure 5 illustrates the correspondence of peak
torques for all DM1 patients obtained with MMT and
QMT. For each patient, the results of his MMT and QMT
scores were plotted one against each other. As observed,
different patients that had different levels of muscle
strength according to the 10 point-scale MMT on the X
axis produced in fact the same torque as indicated by the
QMT values on the Y axis. Several examples are provided
for strength values ranging from 2.5 to 35 Nm, a magni-
tude of strength that corresponds to the range of strength
we would observe with DM1 patients. The weaker the
patients (the lower the QMT peak torques), the more
important the possibility of misclassifying a patient (the
more important the number of possible MMT scores).
For example, the horizontal arrows at the 2.5 and 5 Nm
values on the Y axis are crossing 5 different point scale of
muscle strength, from 2 to 7, as assessed with MMT.
Discussion
The use of a valid and reliable protocol to detect low sub-
maximal muscle impairments in DM1 patients is essen-
tial to characterize the natural history of muscular
involvement and measure the efficacy of short-term ther-
apeutic trials in multicenter studies. The method used to
assess muscle strength must be simple, easy to perform
for the clinician and it must be sensitive enough to allow
the early detection of distal muscle weaknesses. More-
over, the method used must be able to discriminate
between different levels of severity of muscle impair-
ments for choosing the best clinical decisions with regard
to treatment plan.
This study has allowed us to characterize the maximal
isometric strength of ankle evertors and dorsiflexors with
quantitative muscle testing between three levels of sever-
ity of DM1 (mild, moderate and severe) and control sub-
jects in a multicenter study setup. When averaging the
torque values for genders, sides, centers, and days at
baseline, the mean peak torque of the control subjects
was 26.5 Nm. This is similar to the values reported by
Hogrel et al. (2007) that was 30.5 Nm when combining
men and women[19]. The slight difference observed
between studies could be explained by methodological
differences. The values from Hogrel et al. were reported
for a 20-80 year old range compared to a 40-50 decade in
our study, and ankle dorsiflexion measurements were
performed with the knee flexed and against gravity.
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HHD strength values for the ankle dorsiflexors for
healthy subjects for the 40-50 decade of age but unfortu-
nately, the units used in these studies were the Newton
and Newton/Kg, which does take into account the lever
arms and does not allow a proper comparison [20,21].
Our study suggests that the initial decline of muscle
strength in DM1 patients in the first 19 years of the dis-
ease (comparing the change of strength between G0 and
G1) is about 2.5% (evertors) to 3.2% (dorsiflexors) per
year followed by a rate of progression of about 1.5% (dor-
siflexors) to 2.2% (evertors) for the subsequent 11 years.
Using a Nicholas push HHD, Mathieu et al. (2003) previ-
ously reported a strength decline per year of disease
duration of 1.2-1.6% for hip flexors, a proximal group,
and 2.0-3.0% for the hand grip flexors, a distal group[2].
These results concur with our study and suggest that the
lost of strength in distal muscles is progressive and might
be as important for both the upper and lower limbs.
Because our study design was not longitudinal, it is not
possible to know if the progression of the muscle strength
decline is linear or not. Also, as the disease duration is
assessed essentially through the patient's interview, it
remains an estimate which may not be perfectly accurate.
In the current study, both the ankle evertors and dorsi-
flexors were considered. The justification to include the
evertors in the current study was based on the premise
that, near-maximally inverted ankle at footstrike, the
evertors would act in synergy with the ankle dorsiflexors
to stabilize the foot-ankle complex during weight bearing
activities. Because of the consistent muscle weakness of
ankle dorsiflexors reported in the literature in DM1
patients, we hypothesised that the evertors could com-
pensate for a lack of ankle dorsiflexion strength. However,
the current findings suggest that there is no added value
to measure the strength of both the evertor and dorsi-
flexor muscles to follow the progression of the disease in
DM1 patients.
Figure 2 Reproducibility of muscle strength at baseline between Day 1 and Day 21 for the ankle evertors and dorsiflexors for Quebec (n = 
all trials of 21 patients and 7 controls) and Lyon (n = all trials of 24 patients and 9 controls). The equation and coefficients of determination R2 
are indicated for each muscle group and both centres.
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Figure 3 a and b. The top figure shows the mean peak torque and SD of ankle evertors and dorsiflexors of controls (G0) and DM1 patients 
as classified into Group 1 (G1, mild), Group 2 (G2, moderate), and Group 3 (G3, severe) according to the severity of their muscle impairment. 
The bottom figure illustrates the same data pooled for the two study sites.
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ibility of the measures at baseline even when the protocol
was administered by different centers and testers. This
later finding confirms the usefulness of using a HHD pro-
tocol for longitudinal follow-up in a future multicentre
therapeutic trial aimed at assessing the efficacy of a gene
therapy. The present results also confirmed the capacity
of QMT to discriminate between healthy and myotonic
dystrophy type 1 patients with different levels of impair-
ments. Even when manual muscle testing is used by clini-
cians who have several years of experience and are
utilizing a more sensitive tool such as the MM-MRSC 10
point scale, as shown in the present study, it cannot prop-
erly classify DM1 patients. As seen on Figure 5, subjects
with the same peak torque would have been attributed a
score of 2, 3, 4, 5, 6, and even 7. This misclassification
being worse for weaker patients, it may have a significant
negative impact on the clinical decision making. A DM1
patient with a score of 7 with MMT would have been
considered as having a mild muscular impairment while
in fact, using the QMT, he may have had a very low
torque and would therefore have been considered as hav-
ing severe muscle impairment. In this case, this may have
led to classify the patient in a different DM1 group and
may also have led to different clinical recommendations.
This is in agreement with Whittaker et al. (2006) who
concluded that MRC scale is unsuitable for detecting the
small changes in strength seen in a slowly progressive dis-
ease such as myotonic dystrophy[22]. In fact, the mean
torque difference between the control group and the
DM1 patients was ranging from 8.1 to 22.7 Nm. Also, the
smallest mean group difference observed between DM1
patients was 2.3 Nm (between G2 and G3 in eversion), a
difference about twice than the SEM. Therefore, using a
HHD protocol, one can be confident that even small
between group muscle strength differences observed
Table 1: Torque values ± SD* in Newton-meters of ankle evertors and dorsiflexors of all groups (n = number of subjects 
tested) for both centers. 
DM1 - Group 1
(Quebec n = 11)
(Lyon n = 11)
DM1 - Group 2
(Quebec n = 6)
(Lyon n = 6)
DM1 - Group 3
(Quebec n = 5)
(Lyon n = 7)
Control
(Quebec n = 7)
(Lyon n = 9)
Dorsiflexion right left right left right left right left
Quebec 12.8 ± 3.7 12.7 ± 4.9 6.9 ± 2.4 6.3 ± 1.9 3.2 ± 1.1 3.2 ± 1.5 25.8 ± 6.0 24.6 ± 4.6
Lyon 9.4 ± 3.8 9.2 ± 2.8 5.3 ± 2.2 6.2 ± 3.7 2.7 ± 1.5 3.8 ± 1.4 26.8 ± 5.8 26.3 ± 6.2
Eversion
Quebec 12.3 ± 3.8 12.5 ± 5.3 6.0 ± 2.2 6.0 ± 1.7 5.0 ± 2.5 3.8 ± 2.9 19.6 ± 5.1 18.5 ± 3.9
Lyon 8.9 ± 3.2 8.0 ± 3.2 5.2 ± 1.8 4.7 ± 1.5 2.1 ± 2.2 1.8 ± 1.5 18.1 ± 5.0 17.9 ± 4.2
The differences between the three DM1 groups as well as between the DM1 patients and the controls were all statistically significant (p < 0,001). 
However, when comparing the data between Lyon and Quebec, no statistical differences between sites for each group were observed (p > 0.05).
* Standard Deviation
Figure 4 Relationships between the maximal strength (Day 1 and 
D 21 values combined; n = 180 trials) of the ankle evertors and 
dorsiflexors for Quebec and Lyon as estimated with simple linear 
regression. The equation and coefficients of determination R2 are in-
dicated for each centre.
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not only the result of measurement errors.
In addition to verify the feasibility of measuring the iso-
metric muscle strength assessment with DM1 patients
using a hand-held dynamometer protocol, this study is a
preliminary step for the development of a valid, reliable
and responsive outcome for the measurement of muscle
impairment with this population. This measure could be
used to monitor the major stages of DM1 progression,
characterize the natural history of the disease, verify the
efficacy of therapies, and document the relationship
between impairments and disabilities. However, future
research should be done to better characterize the inter-
testers reproducibility using our method and to look at
systematic differences between sessions for other muscle
groups. The present results are very promising and pro-
vide us with the basis we need to move forward and pro-
ceed with a longitudinal study to determine the rate of
muscle strength decline through all stages of the disease
and to verify the potential of quantitative measures of
muscle impairments as a valid indicator of other biologi-
cal changes.
Conclusions
Manual muscle testing, even when used by experimented
clinicians, cannot be used to properly classify DM1
patients. Our results confirm the usefulness of using a
standardized HHD protocol to measure muscle strength
in DM1 patients. The capacity of an HHD protocol to dis-
criminate between healthy and DM1 patients with differ-
ent levels of impairments suggests that this method may
be used as a biological marker for longitudinal follow-
ups.
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